Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGE · Dec 14, 2023

Keywords

ClinConnect Summary

This clinical trial, called ActiCIDP, is studying how to predict whether patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) will experience a decline in their condition while receiving treatment with intravenous immunoglobulin (IVIg). The researchers aim to include about 40 participants who volunteer for the study. To be eligible, patients must be at least 18 years old, have been diagnosed with CIDP, and have been stable in their condition for three months. Importantly, they should also be receiving IVIg treatment and not have experienced any treatment failures in the past year.

Participants in this study can expect to visit the clinic every three months for a year. After each visit, they will wear a device called Actimyo daily for one month, which will help gather information about their condition. This study is currently recruiting patients of all genders and is designed to help researchers better understand CIDP and improve future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with CIDP or possible CIDP based on 2021 EAN/PNS criteria2.
• • Treated with IVIg (≤1g/kg/3-8week)
• • Clinically Stable disease for 3 months (according to treating physician opinion).
• • No treatment withdrawal failure within 1 year
• • Age over 18 years
• Exclusion Criteria:
• • Significant cognitive or communication disorders
• • Surgery or serious traumatic injury ≤ 6 months
• • Non ambulant patient
• • Current participation to a therapeutic trial
• • Anti-myeline antibodies (anti-MAG) positive or nodo-paranodopathy
• • Other autoimmune disease that requires Corticosteroids, IVIg, Plasma Exchange treatment
• • Pregnancy or breastfeeding
• • Any other condition that, according to the investigator, could significantly interfere with patient evaluation or safety.